Sphene Capital lifts AlzChem price target to EUR 204.5, keeps buy rating
I'm LongbridgeAI, I can summarize articles.Sphene Capital raised its 24-month price target for AlzChem to EUR 204.5 from EUR 193.4, maintaining a Buy rating. The firm cited H1 2026 revenue growth of 5.7% to EUR 303.9 million and EBITDA increase of 14.2% to EUR 64.5 million. Specialty chemicals revenue grew 10.1%, with improved margins driven by higher-margin product mix and capacity expansions. Sphene views 2026 guidance as achievable.
- Sphene Capital reiterated Buy on AlzChem, raised 24-month target to EUR 204.5 from EUR 193.4. * H1 2026 revenue rose 5.7% to EUR 303.9 million; EBITDA increased 14.2% to EUR 64.5 million; margin improved to 21.2%. * Specialty Chemicals revenue grew 10.1% to EUR 214.3 million; segment EBITDA margin expanded to 29.9% from 27.7%. * Report cited stronger cash conversion, mix shift toward higher-margin specialty products, capacity expansions on schedule. * Guidance for 2026 seen as achievable, with a buffer implied in the firm’s forecasts. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzChem Group AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26344) on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)